ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.61
+2.01%Sep 11, 2026, 20:27 UTC
Artiva Biotherapeutics, Inc. elected Brian Daniels, M.D. and Laura Stoppel, Ph.D. as Class II directors effective September 8, 2026.
Jun 8, 2026, 10:30 UTC
The U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Artiva Biotherapeutics' AlloNK plus rituximab for refractory rheumatoid arthritis.
Source: